GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2

Conventionally, hyperimmune globulin drugs manufactured from pooled immunoglobulins from vaccinated or convalescent donors have been used in treating infections where no treatment is available. This is especially important where multi-epitope neutralization is required to prevent the development of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizrahi, Rena A., Lin, Wendy Y., Gras, Ashley, Niedecken, Ariel R., Wagner, Ellen K., Keating, Sheila M., Ikon, Nikita, Manickam, Vishal A., Asensio, Michael A., Leong, Jackson, Medina-Cucurella, Angelica V., Benzie, Emily, Carter, Kyle P., Chiang, Yao, Edgar, Robert C., Leong, Renee, Lim, Yoong Wearn, Simons, Jan Fredrik, Spindler, Matthew J., Stadtmiller, Kacy, Wayham, Nicholas, Büscher, Dirk, Terencio, Jose Vicente, Germanio, Clara Di, Chamow, Steven M., Olson, Charles, Pino, Paula A., Park, Jun-Gyu, Hicks, Amberlee, Ye, Chengjin, Garcia-Vilanova, Andreu, Martinez-Sobrido, Luis, Torrelles, Jordi B., Johnson, David S., Adler, Adam S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320065/
https://www.ncbi.nlm.nih.gov/pubmed/35890050
http://dx.doi.org/10.3390/pathogens11070806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320065/
https://www.ncbi.nlm.nih.gov/pubmed/35890050
http://dx.doi.org/10.3390/pathogens11070806

Ejemplares similares